Problem

Cenote addresses the expensive gap between acquiring a healthcare or D2C lead and converting that lead into a purchase. Telehealth clinics may pay hundreds or even thousands of dollars per lead, yet traditional abandoned-checkout outreach can convert less than 1% because generic email and SMS campaigns have low engagement, while human sales representatives cannot respond quickly or cover every lead. The result is revenue leakage and a confusing experience for patients making high-stakes medical decisions.

Its clearest use case is revenue recovery: immediately re-engaging abandoned carts and checkouts, failed payments, and lapsed customers through persistent follow-up. Cenote’s materials position this as converting demand the clinic has already paid to acquire, rather than spending more on acquisition.

Product / Service

Cenote provides HIPAA-compliant AI sales agents that call, text, email, and message prospects through WhatsApp. The agents connect to a customer’s existing operating environment and integrations, reach out as soon as a lead is identified, answer questions, qualify needs, remember the conversation, and continue following up over days or weeks. They can also receive inbound calls when a patient is ready to engage. The company promises a rapid implementation, with its site advertising go-live in seven days and the ability to opt out at any time.

The benefit is scalable, personalized follow-through that feels more like a care guide than an automated campaign. Cenote claims higher conversion from existing traffic and more efficient teams without additional headcount, while its HIPAA and SOC 2 Type 1 and Type 2 compliance materials make the product suitable for health-related interactions.

Market

Cenote competes at the intersection of conversational commerce, healthcare sales automation, patient engagement, and revenue recovery. Its initial focus is telehealth and other digital-health clinics, while the company also describes itself as serving D2C brands internationally. Y Combinator categorizes it as an active B2B Digital Health, E-commerce, and AI company founded in 2024 and backed by its Winter 2025 batch. The main substitutes are one-way marketing automation, call centers, and limited human inside-sales coverage; Crunchbase also identifies Waystar, AKASA, and Tebra as possible alternatives, although the available evidence does not establish them as direct like-for-like competitors.

Cenote appears to have commercial deployments rather than being purely pre-revenue. Its site names telehealth customers Rugiet and Brightmeds: Rugiet reportedly achieved a 42% lift in revenue per lead and a 53% relative conversion-rate lift after going live in one week, with no additional hires, while Brightmeds is reported to have doubled conversion rates. These are company-published case-study claims, so they demonstrate early customer traction but should not be treated as independently audited market share or revenue data.